Do these 3 things before closing this tab:
1Fix the driver behind crashes, sound loss and screen glitches2Repair Windows errors before they cause bigger problems3Scan for outdated or missing drivers - takes under a minuteCipla and Sun Pharma are both large Indian pharmaceutical companies, but they are not interchangeable businesses. In FY2024–25, Sun reported higher revenue and faster growth on its stated measures, while Cipla reported a 25.9% EBITDA margin. Their portfolios and geographic disclosures also differ, and company-reported figures do not by themselves establish which business is stronger or which stock is a better investment.
Which company is larger, and how did each perform?
On reported FY2024–25 revenue, Sun Pharma was larger: it recorded consolidated revenue of ₹520 billion (₹52,000 crore), up 9.0% year over year. Cipla reported revenue from operations of ₹27,548 crore, up 7%. These are company-reported figures for the fiscal year; revenue alone does not measure profitability, growth quality or investment value. Sun Pharma FY2024–25 Annual Report; Cipla FY2024–25 Annual Report.
| # | Preview | Product | Price | |
|---|---|---|---|---|
| 1 |
|
Made in India: The Story of Desh Bandhu Gupta, Lupin and Indian Pharma | $8.00 | Buy on Amazon |
| FY2024–25 reported measure | Cipla | Sun Pharma |
|---|---|---|
| Revenue | ₹27,548 crore revenue from operations; up 7% year over year | ₹520 billion consolidated revenue; up 9.0% year over year |
| EBITDA | ₹7,128 crore; EBITDA margin 25.9% | ₹153 billion; up 17.3% year over year |
| Adjusted net profit | Not stated in the cited headline comparison | ₹120 billion; up 19.0% year over year |
EBITDA and adjusted net profit are company-reported measures, and the information presented here does not establish that every accounting definition is directly comparable. Cipla’s stated margin is useful context for its own results, but should not be set against a Sun margin that is not provided here. Sources: Cipla FY2024–25 Annual Report; Sun Pharma FY2024–25 Annual Report.
How do their businesses differ?
Cipla’s portfolio
Cipla describes its businesses as generics and branded generics, specialty medicines and consumer health. Its company materials also highlight geographic portfolios including One India, North America, South Africa, and Emerging Markets and Europe. In India, Cipla says its generics business works with more than 4,000 partners in a fragmented market with more than 5,000 pharmaceutical players; those counts are company statements. Cipla: Our Offerings.
Sun Pharma’s portfolio
Sun lists generic and branded medicines, specialty medicines, over-the-counter products, active pharmaceutical ingredients (APIs) and intermediates. Its product page describes a presence in more than 100 countries and a portfolio of more than 2,000 molecules, with dosage forms including tablets, capsules, injectables, inhalers, ointments, creams and liquids. These are company-provided portfolio descriptions, not a matched comparison of segment revenues. Sun Pharma: Our Product Portfolio.
Specialty medicines are a stated growth and investment focus for Sun. The company reported that global specialty contributed 20% of consolidated revenue in FY2024–25, compared with 18% in FY2023–24, and that specialty R&D spending was US$154 million in FY2024–25. Investment and a rising revenue share indicate strategic emphasis, not guaranteed future returns. Sun Pharma FY2024–25 Annual Report.
What do the geographic figures show?
The reported examples point to different areas of exposure, but they use different geographies and denominators. They are not a ranking of diversification or market strength.
- Cipla in Africa: One Africa revenue was ₹3,827 crore in FY2024–25, with growth of 14% excluding the QCIL divestment. South Africa revenue was ZAR 6.3 billion, up 15% in local currency in FY2024–25. Cipla FY2024–25 Annual Report.
- Sun in India: India revenue was ₹169,230 million, or 33% of revenue, in FY2024–25. Sun reported an 8.3% India market share based on AIOCD AWACS data for the 12 months ended March 2025. Sun Pharma FY2024–25 Annual Report.
Sun’s stated presence in more than 100 countries suggests broad reach, while Cipla’s disclosures identify multiple regional portfolios. Broad reach can diversify sources of demand, but it can also mean operating across more regulatory and supply environments. That is an analytical implication of the companies’ descriptions, not a quantified comparison of their geographic risk.
PC Slower Than It Used to Be?
A free scan shows the junk files, broken settings and background clutter dragging Windows down - then fixes them in one click.Free scan · Windows 10 & 11Crashes, No Sound, or Screen Glitches?
Random freezes, missing sound and display glitches usually trace back to one bad driver. Find and replace yours safely.Free scan · under a minuteWhat are the main business risks?
Pricing pressure and competition
Sun’s management describes price erosion in parts of the generic business, including in the United States, and says healthcare buyers are seeking value. Cipla describes India’s generics market as highly competitive and fragmented, with uncertainty involving trade margins and policy. These are company descriptions of their respective operating contexts; the cited material does not quantify comparable price sensitivity for the two companies. Sun Pharma FY2024–25 Annual Report; Cipla: Our Offerings.
Regulation and approvals
Cipla identifies uncertainty around trade margins, branded-generic policy, the Drug Price Control Order (DPCO) and product approvals in India. Sun points to differing regulatory environments across the countries where it operates. A regulatory change can affect approvals, pricing or the ability to sell products, but the cited disclosures do not provide a like-for-like estimate of the resulting financial impact. Cipla: Our Offerings; Sun Pharma: Our Product Portfolio; Sun Pharma FY2024–25 Annual Report.
Supply reliability and geopolitical conditions
Sun’s FY2024–25 report discusses medicine-availability disruptions during the pandemic, supply-chain changes, local sourcing and geopolitical uncertainty around medicine supply. It also describes onshoring and nearshoring as broader industry trends. These are reported risk themes, not evidence that either company is currently experiencing a particular shortage or disruption. Sun Pharma FY2024–25 Annual Report.
Execution of portfolio plans
Sun presents specialty medicines as an investment priority. Cipla’s FY2024–25 report identifies investment areas including inhalation therapies, complex generics, peptide injectables, oligonucleotides and differentiated 505(b)(2) products. These strategies depend on development, approvals and commercial execution; the cited reports do not quantify the probability or future returns of those plans. Sun Pharma FY2024–25 Annual Report; Cipla FY2024–25 Annual Report.
Quick wins for a faster PC:
Fix the driver behind crashes, sound loss and screen glitchesFind Drivers →Clear out junk files and repair common Windows errorsFree Scan →What can—and can’t—this comparison tell an investor?
For FY2024–25, Sun reported greater revenue and stronger year-over-year growth on its headline revenue, EBITDA and adjusted-net-profit measures. Cipla reported its own EBITDA and margin figures, but the available measures here do not support a complete like-for-like profitability comparison. The portfolio descriptions and selected regional figures help explain how the businesses differ, but they do not establish a winner on diversification, resilience or future performance.
The figures and risk themes above come from company-authored reports and pages. They are useful for understanding what each company reports about its business, not independent verification or a stock recommendation. This comparison does not assess valuation, future earnings, comparable segment sensitivities or whether either share suits a particular investor.
Quick Recap
Product prices and availability are accurate as of the date/time indicated and are subject to change. Any price and availability information displayed on Amazon at the time of purchase will apply.
